A phase 1, first-in-human study of IB-T101, an OUTLAST CAR-T product for the treatment of CD70-positive clear cell renal carcinoma.

Authors: Matthias Schroff, Bo Liu, Warren Anderson, Mathew Esquivel, Adam Pecoraro, Kate Fagan-Solis, Yuning Lei, Jun Cui, Yarong Liu, Kevin Carbajal, Maximilian Richter

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps2676

Source: Full article

---

Abstract

TPS2676